# Genflow nears key data readout for SIRT6 gene therapy platform

- Link: https://www.directorstalkinterviews.com/genflow-nears-key-data-readout-for-sirt6-gene-therapy-platform/4121259374
- Published: 2026-08-05T10:10:00+01:00
- Author: Amilia Stone

Genflow Biosciences is approaching an important stage in the development of its 
SIRT6 gene therapy platform, with further data from its aged-dog studies expected
shortly and a new delivery partnership now in place.

The company said early effects seen in its Sarcopenia and Longevity in Aged Beagles
study were still present three months after treatment. The blinded trial includes
24 beagles aged over 10 years and is testing two naked DNA doses, an AAV8 viral 
vector treatment and an untreated control group.

Initial results released earlier in 2026 showed that all three treated groups had
better survival during the dosing period than the control group. No adverse events
were reported. Genflow later confirmed that the observed improvements remained visible
three months after dosing and that no new safety concerns had emerged.

The findings are still preliminary. The company is continuing to analyse muscle 
biopsies and methylation clock data, which should provide a clearer view of whether
the treatment is affecting biological ageing, muscle condition or both.

Genflow’s lead therapy, GF-1002, uses a variant of the SIRT6 gene linked to exceptional
human longevity. SIRT6 is involved in DNA repair, genomic stability and the cellular
response to stress. The company is developing a centenarian-associated form of the
gene rather than the standard version.

The current study is also testing different ways to deliver the therapy. Naked DNA
is simpler and may be cheaper to produce, but uptake into cells can be limited. 
AAV8 viral vectors can support longer-lasting gene expression, although repeat dosing
and existing immunity may create constraints.

Genflow is also developing a messenger RNA approach using lipid nanoparticles. This
method would produce temporary gene expression and may allow repeat administration.
Its value will depend on whether the formulation can reach the required tissues 
efficiently.

To advance this work, Genflow has entered a collaboration with Acuitas Therapeutics.
Acuitas will formulate Genflow’s SIRT6 messenger RNA using its lipid nanoparticle
technology and return the finished formulations for preclinical testing.

Acuitas is funding the work, making the programme non-dilutive for Genflow shareholders.
The deal is not expected to generate immediate revenue, but it gives Genflow access
to specialist delivery technology without requiring it to carry the full development
cost.

_**[Genflow Biosciences plc](https://www.directorstalkinterviews.com/company/genflow-biosciences-plc/genf.l)**(
LON:GENF, OTCQB:GENFF, FRA:WQ5) is a UK-based biotech firm with R&D facilities in
Belgium focused on developing novel therapeutic approaches that potentially halt
or slow the aging process in humans and dogs supporting longer, healthier lives_

Share on: